

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ImExHS Limited (formerly Omni Market Tide Ltd)

ABN

60 096 687 839

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

1	+Class of +securities issued or to be issued	<ol style="list-style-type: none"> <li>1. Fully paid ordinary shares</li> <li>2. Fully paid ordinary shares</li> <li>3. Fully paid ordinary shares</li> <li>4. Fully paid ordinary shares</li> <li>5. Unlisted Consideration Options</li> <li>6. Unlisted New Options</li> <li>7. Unlisted Adviser Options</li> </ol>
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	<ol style="list-style-type: none"> <li>1. 220,000,000</li> <li>2. 520,000,000</li> <li>3. 10,000,000</li> <li>4. 25,000,000</li> <li>5. 150,000,000</li> <li>6. 12,500,000</li> <li>7. 30,000,000</li> </ol>

---

+ See chapter 19 for defined terms.

- |  |  |
|--|--|
| <p>3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)</p> | <ol style="list-style-type: none"> <li>1. Same as existing fully paid ordinary shares</li> <li>2. Same as existing fully paid ordinary shares subject to escrow for 24 months from date of re-quotatation</li> <li>3. Same as existing fully paid ordinary shares subject to escrow for 24 months from date of re-quotatation</li> <li>4. Same as existing fully paid ordinary shares.</li> <li>5. Unlisted Consideration Options, comprising:             <ol style="list-style-type: none"> <li>(a) 50,000,000 Class A Consideration Options exercisable at \$0.05 on or before 30 June 2021 and subject to escrow for 24 months from date of re-quotatation, with an issue price of \$0.00001 per option</li> <li>(b) 50,000,000 Class B Consideration Options exercisable at \$0.0375 on or before 28 August 2023 and subject to escrow for 24 months from date of re-quotatation. The Options vest on ImExHS achieving an EBIT exceeding \$5,000,000 in any rolling period of four quarters</li> <li>(c) 50,000,000 Class C Consideration Options exercisable at \$0.0375 on or before 28 August 2023 and subject to escrow for 24 months from date of re-quotatation. The Options vest on ImExHS achieving an EBIT exceeding \$7,500,000 in any rolling period of four quarters</li> </ol> </li> <li>6. Unlisted New Options exercisable at \$0.0375 on or before 30 June 2021 and subject to escrow until 14 May 2019.</li> <li>7. Unlisted Adviser Options exercisable at \$0.05 on or before 30 June 2021 and subject to escrow for 24 months from date of re-quotatation, with an issue price of \$0.00001 per option</li> </ol> |
|--|--|

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<ol style="list-style-type: none"> <li>1. Yes - the fully paid ordinary shares will rank equally with existing quoted fully paid ordinary shares</li> <li>2. Yes - the fully paid ordinary shares will rank equally with existing quoted fully paid ordinary shares but are subject to 24 months escrow from the date of re-quotation</li> <li>3. Yes - the fully paid ordinary shares will rank equally with existing quoted fully paid ordinary shares but are subject to 24 months escrow from the date of re-quotation</li> <li>4. Yes - the fully paid ordinary shares will rank equally with existing quoted fully paid ordinary shares</li> <li>5. No – but shares issued upon exercise of options will rank equally in respects from the date of issue with existing fully paid ordinary shares</li> <li>6. No – but shares issued upon exercise and conversion will rank equally in respects from the date of issue with existing fully paid ordinary shares and subject to escrow until 14 May 2019.</li> <li>7. No – but shares issued upon exercise and conversion will rank equally in respects from the date of issue with existing fully paid ordinary shares</li> </ol>
<p>5 Issue price or consideration</p>	<ol style="list-style-type: none"> <li>1. \$0.025 per share (Public Offer)</li> <li>2. Nil – issued to ImExHS shareholders as part of the consideration for the acquisition of ImExHS</li> <li>3. Nil – issued to ImExHS shareholders as part of the consideration for the acquisition of ImExHS</li> <li>4. Nil</li> <li>5. \$0.00001 per Class A Consideration Option. Nil for Class B Consideration Options and Class C Consideration Options.</li> <li>6. Nil</li> <li>7. \$0.00001 per Adviser Option</li> </ol>

---

+ See chapter 19 for defined terms.

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<p>Securities issued as consideration for the acquisition of issued capital in ImExHS and to re-comply with Chapters 1 and 2 of the Listing Rules</p> <p>Funds raised will be used for the following key business activities:</p> <ul style="list-style-type: none"> <li>• sales and marketing;</li> <li>• TGA approvals and Australia soft launch;</li> <li>• FDA approvals and U.S. soft launch;</li> <li>• research and development;</li> <li>• costs of the offers; and</li> <li>• corporate administration and working capital.</li> </ul> <p>Further details of the use of funds are provided in the Prospectus dated 23 July 2018 (as supplemented).</p>
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A

6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A							
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1							
7	<p>+Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	28 August 2018							
8	Number and +class of all +securities quoted on ASX ( <i>including</i> the +securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="790 907 1085 947">Number</th> <th data-bbox="1085 907 1388 947">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="790 947 1085 1041">395,657,180</td> <td data-bbox="1085 947 1388 1041">Fully paid ordinary Shares</td> </tr> <tr> <td data-bbox="790 1041 1085 1180">2,500,006</td> <td data-bbox="1085 1041 1388 1180">Options exercisable at \$1.00 on or before 31 December 2018</td> </tr> </tbody> </table>	Number	+Class	395,657,180	Fully paid ordinary Shares	2,500,006	Options exercisable at \$1.00 on or before 31 December 2018	
Number	+Class								
395,657,180	Fully paid ordinary Shares								
2,500,006	Options exercisable at \$1.00 on or before 31 December 2018								

	Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	<p>530,000,000 Fully paid ordinary shares escrowed 24 months from re-quotation</p> <p>3,000,000 Class A Performance Shares</p> <p>35,000,000 Options exercisable at \$0.025 expiring 31/3/2021</p> <p>50,000,000 Class A Consideration Options exercisable at \$0.05, expiring 30/6/2021 and escrowed 24 months from re-quotation</p> <p>50,000,000 Class B Consideration Options exercisable at \$0.0375, expiring 28/8/2023, escrowed 24 months from re-quotation and subject to vesting conditions.</p> <p>50,000,000 Class B Consideration Options exercisable at \$0.0375, expiring 28/8/2023, escrowed 24 months from re-quotation and subject to vesting conditions.</p> <p>12,500,000 New Options exercisable at \$0.0375, expiring 20/6/2021 and are subject to escrow until 14 May 2019.</p> <p>30,000,000 Adviser Options exercisable at \$0.05, expiring 20/6/2021 and escrowed 24 months from re-quotation</p>
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A

## Part 2 - Pro rata issue

- |    |  |  |
|----|--|--|
| 11 | Is security holder approval required?  |  |
| 12 | Is the issue renounceable or non-renounceable?   |  |
| 13 | Ratio in which the +securities will be offered   |  |
| 14 | +Class of +securities to which the offer relates   |  |
| 15 | +Record date to determine entitlements   |  |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?   |  |
| 17 | Policy for deciding entitlements in relation to fractions  |  |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents<br><br><small>Note: Security holders must be told how their entitlements are to be dealt with.<br/>Cross reference: rule 7.7.</small> |  |
| 19 | Closing date for receipt of acceptances or renunciations   |  |

---

+ See chapter 19 for defined terms.

- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?

---

+ See chapter 19 for defined terms.



32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Issue date

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of <sup>+</sup>securities  
(tick one)

(a)  <sup>+</sup>Securities described in Part 1

(b)  All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders

36  If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional <sup>+</sup>securities

---

<sup>+</sup> See chapter 19 for defined terms.

**Entities that have ticked box 34(b)**

38 Number of +securities for which +quotation is sought

39 +Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		

---

+ See chapter 19 for defined terms.

## Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.


- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:  ..... Date: 28 August 2018  
(Company secretary)

Print name: Peter Webse.....

== == == == ==

---

+ See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b><i>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</i></b>	
<b><i>Insert</i></b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	150,657,180
<b><i>Add</i></b> the following: <ul style="list-style-type: none"> <li>• Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> <b><i>Note:</i></b> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	775,000,000 shares as approved by shareholders on 31 July 2018
<b><i>Subtract</i></b> the number of fully paid +ordinary securities cancelled during that 12 month period	-
<b>“A”</b>	925,657,180

+ See chapter 19 for defined terms.

<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A” by 0.15</b>	138,848,577
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	-
“C”	-
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	138,848,577
<b>Subtract “C”</b> <i>Note: number must be same as shown in Step 3</i>	-
<b>Total</b> [“A” x 0.15] – “C”	138,848,577 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

## Part 2 – N/A

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<p><b>“A”</b></p> <p><i>Note: number must be same as shown in Step 1 of Part 1</i></p>	
<b>Step 2: Calculate 10% of “A”</b>	
<p><b>“D”</b></p>	<p>0.10</p> <p><i>Note: this value cannot be changed</i></p>
<b>Multiply “A” by 0.10</b>	
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<p><b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</p> <p><i>Notes:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	
<p><b>“E”</b></p>	

+ See chapter 19 for defined terms.

<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
<p>“A” x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	
<p><b>Subtract “E”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	
<p><b>Total</b> [“A” x 0.10] – “E”</p>	<p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

---

+ See chapter 19 for defined terms.